Stéphane Bancel: Moderna’s biotech whizz who changed the world

Stéphane Bancel had a safe job as CEO of a French multinational when he decided to risk it all on a promising but unproven medical technology. The bet paid off handsomely.

If Stéphane Bancel ever questioned his ability to move markets, he got his answer last week. The Moderna CEO’s observation that existing vaccines will be less effective at tackling Omicron than earlier strains of Covid-19 rattled investors sufficiently to spark another global lurch downwards, says the Financial Times. The mood has since lightened – there are signs the variant may prove less serious than feared. But Moderna and other vaccine-makers still have their work cut out. Bancel reckons Moderna could make between two and three billion Omicron-targeted doses next year, but it’s a balancing act. “It would be risky,” he says, to shift the entire production capacity into the fight when other variants are still in circulation.

At the vanguard of science

Moderna is now such a household name that it’s almost a shock to recall that its sole commercial product is the Covid-19 vaccine. “Before the pandemic, Moderna was simply a heavily loss-making biotech with unproven technology,” says The Sunday Times. But delivery of its mRNA jab “has cemented its place at the vanguard of scientific discovery”. It has also made a small fortune for Bancel, who owns around 8% of the Cambridge, Massachusetts-based outfit’s shares, which have jumped by more than 1,000% since it floated on Nasdaq in 2018. In just over a decade since Moderna was founded – on the-then radical hunch that mRNA could be used to treat cancer, diabetes and genetic diseases – its market value has shot up to nearly $115bn. As a peer observes: “The pandemic came almost as a blessing to prove the technology”.

According to early investor Baillie Gifford, the pugnacious Frenchman has always stood out from the crowd as “a relentless risk optimiser”. Bancel famously quit a “safe job”, as CEO of the French diagnostics multinational BioMérieux, to join the fledgling Moderna in 2011 – telling his photographer wife, Brenda, there was just a 5% chance that its “crazy idea” would work. As he observed on a recent Distillations podcast, he couldn’t forego the “chance of changing medicine forever”. 

The emperor was clothed

Born in 1972, Bancel grew up in Marseilles, the son of an engineer and a doctor – fusing these professions into his own life when he chose to study biomolecular engineering at École Centrale in Paris. His subsequent move to Minnesota for a masters opened up the world of US business. Bancel’s first job was at BioMérieux, which had sponsored his MBA at Harvard. At 29 he joined the US drug-maker Eli Lilly, before returning to lead BioMérieux when he was just 34.

In Moderna’s early days, cash was so tight it often struggled to keep the lights on for six months at a time. Bancel, who had “an almost messianic reverence for the mRNA technology”, took an all or nothing approach: you either got with the plot, or you were out, noted industry journal Stat in 2016. Reports of conflicts and defections multiplied – even as Bancel succeeded in persuading the industry’s big-hitters of Moderna’s potential (forging a transforming $240m partnership with AstraZeneca in 2013). He later consulted the HR departments of some tech firms for “tips on employee retention”. The charge of scientific critics back then was that Moderna was “a case of emperor’s new clothes”. Whatever Bancel’s current challenges, he has been vindicated. As the world queues up for Moderna shots, you don’t hear much talk of naked emperors.

Recommended

Cryptocurrency roundup: Putin backs crypto-mining, and spoof McDonald’s coin takes off
Bitcoin & crypto

Cryptocurrency roundup: Putin backs crypto-mining, and spoof McDonald’s coin takes off

Saloni Sardana looks at the cryptocurrency stories that caught our eye this week.
28 Jan 2022
Are recession fears justified? Maybe it’s time to look on the bright side
Economy

Are recession fears justified? Maybe it’s time to look on the bright side

There's a lot to feel nervous about right now, and many people are worrying about an impending recession. But it's by no means certain, says John Step…
28 Jan 2022
Making money is about to get much harder
Investment strategy

Making money is about to get much harder

Soaring inflation, geopolitical risk, bubbly stockmarkets - getting a return on your investment is going to get much more difficult – but not impossib…
28 Jan 2022
How to invest in the chipmakers fixing the semiconductor shortage
Share tips

How to invest in the chipmakers fixing the semiconductor shortage

Last year’s chip crunch brought home how dependent the world is on these tiny pieces of silicon. Chipmakers are rushing to build new factories. Will t…
28 Jan 2022

Most Popular

Amazon halts plans to ban UK Visa credit card payments
Personal finance

Amazon halts plans to ban UK Visa credit card payments

Amazon has said that it is to shelve its proposed ban on UK customers making payments with Visa credit cards.
17 Jan 2022
Shareholder capitalism: why we must return power to listed companies’ ultimate owners
Investment strategy

Shareholder capitalism: why we must return power to listed companies’ ultimate owners

Under our system of shareholder capitalism it's not fund managers, it‘s the individual investors – the company's ultimate owners – who should be telli…
24 Jan 2022
Temple Bar’s Ian Lance and Nick Purves: the essence of value investing
Investment strategy

Temple Bar’s Ian Lance and Nick Purves: the essence of value investing

Ian Lance and Nick Purves of the Temple Bar investment trust explain the essence of “value investing” – buying something for less than its intrinsic v…
14 Jan 2022